Guidelines on the treatment with integrated traditional Chinese medicine and western medicine for severe coronavirus disease 2019
Zhiyu Li(Zhejiang Chinese Medical University), Chengping Wen(Zhejiang Chinese Medical University), Yuepeng Jiang(Zhejiang Chinese Medical University), Yan Gao(Jiangsu University), Weidong G. Lai(Zhejiang Chinese Medical University), Wenqing Luo(Zhejiang Chinese Medical University), Anran Xi(Zhejiang Chinese Medical University), Ke-Er Wang(Zhejiang Chinese Medical University), Xiaofeng Xu(Zhejiang Chinese Medical University), Haichang Li(The Ohio State University), Yaolong Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhijun Xie(Zhejiang Chinese Medical University), Dianming Li(Harbin Electric Corporation (China)), Shouyuan Wu(Lanzhou University), Yu Lou(First Affiliated Hospital of Harbin Medical University), Hui Y. Lan(Chinese University of Hong Kong, Shenzhen), Yi Zhang(Zhejiang Chinese Medical University), Yuanfang He(Zhejiang Chinese Medical University), Shan Fang(Zhejiang Chinese Medical University), Qiangqiang Guo(Lanzhou University), Siyue Song(Zhejiang Chinese Medical University), Yi-Ni Gao(Zhejiang Chinese Medical University), Lin Li(Tongji Hospital), Jiao Chen(Ministry of Education of the People's Republic of China), Ming Zhang(Jiangxi Provincial People's Hospital), Juanjuan Zhang(Lanzhou University), Jianjian Wang(Lanzhou University), Fengqi Zhang(Zhejiang Chinese Medical University), Wu Chen(Zhejiang Chinese Medical University), Xianghui Wen(Zhejiang Chinese Medical University), Xia-Feng Zhang(Zhejiang Chinese Medical University), Qiuping Liu(Zhoukou Normal University), Mingqian Zhou(Zhejiang Chinese Medical University)
Cited by 32
Related Papers
Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2
|Hypertension|2003|790
Comorbidities and multi-organ injuries in the treatment of COVID-19
|The Lancet|2020|669
TGF-β/Smad signaling in renal fibrosis
|Frontiers in Physiology|2015|648
miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes
|Diabetologia|2013|353